Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth

Fig. 1

Indo5 inhibits the biological activities of HGF/c-Met and its downstream signaling pathways. (a) Structure of Indo5. (b) MDCK cells were pretreated with Indo5 for 2 h and then treated with HGF (20 ng/ml) for 12 h. The cell scattering was analyzed. (c) Mouse hepatocytes were pretreated with indicated doses of Indo5 for 2 h and then treated with HGF (20 ng/ml) for 48 h. Cell proliferation was analyzed with MTS assay. (d) HepG2 cells were pretreated with Indo5 for 2 h and then stimulated to migrate with 20 ng/ml HGF. The number of cells that migrated was measured 24 h later. (e) Matrigel plug assay with Indo5 treatment. (f) Effect of Indo5 on the growth of MHCC97H, Ba/F3-Tpr-Met and wild type Ba/F3 cells (g). Apoptosis of Ba/F3-Tpr-Met cells was analyzed with 0.5 μM Indo5 treatment at the indicated time (h). (I) HepG2 cells were pretreated with the indicated doses of Indo5 for 2 h and then treated with HGF (20 ng/ml) for 5 min. (j) MHCC97H cells were treated with different doses of Indo5 for 2 h. Crizotinib treatment (0.5 μM) was used as positive control. (k) Ba/F3-Tpr-Met cells were treated with the indicated doses of Indo5 for 2 h. Then, total cell lysates were prepared for Western blot using the indicated antibodies

Back to article page